Association of increased age with decreased response to intravesical instillation of Bacille Calmette-Guérin in patients with high-risk non-muscle invasive bladder cancer: Retrospective multi-institute results from the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG.

[1]  P. Spiess,et al.  Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review. , 2022, Urologic oncology.

[2]  Nobufumi Ueda,et al.  Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer , 2021, Current urology.

[3]  H. Nishiyama,et al.  The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells , 2021, Cancer Immunology, Immunotherapy.

[4]  F. Pisano,et al.  Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer , 2020, World Journal of Urology.

[5]  G. Stallone,et al.  The impact of age on intravesical instillation of Bacille Calmette–Guerin treatment in patients with high-grade T1 bladder cancer , 2019, Medicine.

[6]  E. Kikuchi,et al.  Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy. , 2017, Urologic oncology.

[7]  T. Karantanos,et al.  Immunotherapy comes of age: Immune aging & checkpoint inhibitors. , 2017, Journal of geriatric oncology.

[8]  G. Pawelec.  Immunosenescence and cancer , 2017, Biogerontology.

[9]  S. Moschos,et al.  Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. , 2016, Cancer treatment reviews.

[10]  M. Glickman,et al.  The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.

[11]  E. Kikuchi,et al.  Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? , 2011, Japanese journal of clinical oncology.

[12]  G. Pawelec,et al.  Potential role of immunosenescence in cancer development , 2010, Annals of the New York Academy of Sciences.

[13]  M. Milowsky,et al.  Bladder cancer in the elderly. , 2009, Urologic oncology.

[14]  Sandy Chang,et al.  Telomere dysfunction and tumour suppression: the senescence connection , 2008, Nature Reviews Cancer.

[15]  C. Sanders,et al.  Late age (85 years or older) peak incidence of bladder cancer. , 2008, The Journal of urology.

[16]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[17]  M. Terris,et al.  Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. , 2008, Urologic oncology.

[18]  H. Herr.  Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. , 2007, Urology.

[19]  Haesook T. Kim.  Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.

[20]  Brian J. Smith,et al.  The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. , 2006, The Journal of urology.

[21]  T. D. Reijke,et al.  Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin , 2016 .

[22]  J. Campisi.  Analysis of tumor suppressor gene-induced senescence. , 2003, Methods in molecular biology.